Most Clicked SNMMI SmartBrief Stories

1. Bayer suspends radium-223 production

SNMMI SmartBrief | Oct 17, 2014

Bayer HealthCare Pharmaceuticals has halted production of prostate cancer drug radium-223, sold as Xofigo, because of problems with manufacturing. Supplies of the drug have been limited since Oct. 7, according to the FDA. Bayer said it is communicating with the FDA and providers about the issue, but it had no estimate regarding when production will resume. OncLive (10/15)

2. Tc-99m prices expected to rise, Mallinckrodt warns

SNMMI SmartBrief | Oct 21, 2014

Technetium-99m prices are expected to rise in the coming years, according to Mallinckrodt. Rising molybdenum-99 production costs are to blame, including converting to use of low-enriched uranium and other factors. (free registration) (10/17)

3. Review finds SPECT and PET useful in ischemic stroke management

SNMMI SmartBrief | Oct 16, 2014

SPECT and PET imaging could greatly improve stroke management, and a hybrid system could provide comprehensive clinical information about the condition, according to a review in the Journal of Nuclear Medicine. PET can be teamed with either CT or MR in monitoring pathophysiologic changes involved in ischemic stroke, and SPECT can be used in terms of cerebral blood volume, perfusion and hemodynamics. PET radionuclides such as C-11, O-15 and F-18 for cerebral blood volume and emerging F-18 galacto-RGD show promise in assessing angiogenesis and revascularization following stroke. (10/15)

4. OctreoPharm's radiotracer gains orphan drug status in U.S.

SNMMI SmartBrief | Oct 21, 2014

OctreoPharm Sciences' new radiotracer OPS202 has received orphan drug status from the FDA for the management of neuroendocrine tumors. OPS202 is based on an advanced antagonistic somatostatin analog with better binding properties, and it can deliver a therapeutic agent at levels as much as five times higher than second-generation agents. Pharmaceutical Business Review Online (10/17)

5. Study IDs sensitive brain areas where networks come together

SNMMI SmartBrief | Oct 15, 2014

Using data from the Iowa Neurological Patient Registry, scientists have mapped six neurological regions they call hubs, where multiple brain networks come together, and they argue that damage to such areas disrupts multiple functions. The findings could shed light on why some people experience substantial cognitive impairment following a relatively minor brain injury. The study appeared in the Proceedings of the National Academy of Sciences. Medical News Today (10/14)

6. Ketamine rapidly reverses symptom of bipolar disorder

SNMMI SmartBrief | Oct 21, 2014

An NIH study published in the journal Translational Psychiatry showed that a single infusion of ketamine reversed anhedonia, the inability to look forward to activities that bring pleasure, in treatment-resistant bipolar disorder. The drug took effect within 40 minutes, and the effects lasted as long as two weeks. PET scans showed the drug sparked activity in the dorsal anterior cingulate cortex. (10/20)

7. N.H. breast-imaging device startup obtains $6.5M

SNMMI SmartBrief | Oct 17, 2014

A regulatory filing shows that Gamma Medica has obtained $6.5 million in its latest funding round. The New Hampshire-based startup makes the LumaGEM molecular imaging system, an FDA-cleared device used as an ancillary tool to mammography in diagnosing breast cancer in women with dense breasts. (10/15)

8. "Updates on Ga-68: Outlook for the Future" webinar Thursday at 3 p.m. ET

SNMMI SmartBrief | Oct 20, 2014

Join David W. Dick, Ph.D. — October 23 at 3 p.m. ET — for a one-hour webinar focusing on current trials underway using the three Ga-68 DOTA agents (NOC/TATE/TOC), along with updates on the manufacturing, production and availability of the agents for clinical and/or investigational use. Learn more and register today. Blank (03/19)

9. Agents show promise in colorectal cancer detection

SNMMI SmartBrief | Oct 17, 2014

A study in the journal PLOS One suggests that Cellectar Biosciences' phospholipid ether analog agents CLR1502 and iodine-131 CLR1404 could provide better localization of primary and metastatic tumors in patients with colorectal cancer. Findings revealed that CLR1502 uptake in intestinal tumors distinguished malignant from nonmalignant tissues in animal models and could also detect regional lymph nodes, while iodine-131 CLR1404 was taken up by colon cancer metastases in humans and could be used in PET. (free registration) (10/16)

10. Lymphoseek gains expanded diagnostic indications

SNMMI SmartBrief | Oct 16, 2014

The FDA has approved Navidea Biopharmaceuticals' supplemental new drug application for Lymphoseek injection for use in preoperative imaging and lymphatic mapping in patients with solid tumors and in sentinel lymph node detection in breast cancer and melanoma. The FDA's approval action letter requires Navidea to conduct a study using Lymphoseek in pediatric patients with solid tumor cancer, to be submitted in 2018. (free registration) (10/15) OncLive (10/15)

Sign up for SNMMI SmartBrief

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession. Learn more